ADAM17 and rheumatoid arthritis: In the present study, serum concentration of ADAM17 was reduced after ABT therapy in RA patients, suggesting that deactivation and decreased numbers of T lymphocytes induced by ABT may be in part responsible for the reduction of ADAM17 levels.